DNA Vaccines Market Intelligence

best-value

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)

feature

 No Additional Benefits

Subscription Benefits:

  • PRO access to New Beroe LiVE*
  • Unlimited updates on the Report*
  • Supplier Watchlist for 3 suppliers*
  • Supplier Shortlisting Tool*

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)

feature

*These features will be unlocked on the new Beroe LiVE when it launches (Q3, 2020)

Are you looking for answers on DNA Vaccines category?

Are you looking for answers on DNA Vaccines category?

  • What are the key trends in DNA Vaccines category?
  • Am I paying the right price?
  • Am I working with the right supplier?
  • What are the major challenges and risks in DNA Vaccines industry?
  • How is DNA Vaccines industry performing?

Over 50,000+ users trust Beroe

Report Coverage

  • Market Analysis
  • Industry Best Practices
  • Best Practices: Pricing Model
  • Sustainability

Table of Contents

  1. Executive Summary
  2. Executive Summary
  3. COVID-19 Update
  1. COVID-19 Update
  2. COVID-19 Update
  1. Market Analysis
  2. Category Definition
  3. Global Market Size
  4. Porter’s Five Forces Analysis
  1. Industry Best Practices
  2. Best Practices: Pricing Model
  3. Sourcing Alternatives
  1. Innovation Framework
  2. Innovations
  1. Sustainability
  2. Sustainability

Want a more detailed personalised report?

DNA Vaccines Global Market Outlook:

Market Growth:

CAGR Growth Rate: 26–28 percent between 2019 and 2025.

2019 Market Value: $1.2 billion.

Market Drivers:

  • Rising prevalence of cancer and infectious diseases
  • Technical expertise and large-scale manufacturing scalability
  • Strategic collaborations between pharma and ARO
  • Advances in delivery mechanism of DNA vaccines through nanotechnology

Porter's Analysis on DNA Vaccines

Supplier Power

  • Supplier understanding of manufacturing synthetic DNA, pDNA, and developing a preprimary DNA platform gives them an upper hand. Also, there is a huge FTE rate gap among Europe (except eastern Europe) and the US-based suppliers from their counterparts in India and China

Barriers to New Entrants

  • Expertise, technology, and cost are the components driving the category in general, so any new entrant with a particular expertise in a therapeutic area or with adoption of new technology, start working as an independent entity
  • Many of the suppliers are an offshoot of the bigger enterprises

Intensity of Rivalry

  • The DNA vaccine market is a fragmented in veterinary medicine, dominated by tier-1 companies, while the human DNA vaccine market is still at its infancy and dominated by niche players and research institutes

Threat of Substitutes

  • Other vaccine development platforms: Alternative vaccine development platforms for instance those that are mRNA based, GreVac (TM), a genetic platform that can expedite the vaccine delivery and production, Tonix’s proprietary horsepox vaccine platform, etc., could hamper this particular market

Buyer Power

  • Pharma companies are leveraging low- cost countries (mostly, India and China) to consolidate on services, like custom synthesis, analytical testing, and manufacturing. Lower cost and process efficiency are given the highest priority in this type of outsourcing. FFS or FTEs are the most adopted contract models for this type of outsourcing

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)

feature

Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.

x

COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)